Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Ganga Pharmaceuticals's net current asset value per share for the quarter that ended in Mar. 2026 was ₹10.53.
The historical rank and industry rank for Ganga Pharmaceuticals's Net Current Asset Value or its related term are showing as below:
BOM:539680'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.98 Med: 1.64 Max: 2.84
Current: 1.14
During the past 12 years, the highest Price-to-Net-Current-Asset-Value Ratio of Ganga Pharmaceuticals was 2.84. The lowest was 0.98. And the median was 1.64.
BOM:539680's Price-to-Net-Current-Asset-Value is not ranked
in the Drug Manufacturers industry.
Industry Median: 5.7
vs BOM:539680: 1.14
Ganga Pharmaceuticals (BOM:539680) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Ganga Pharmaceuticals Net Current Asset Value Related Terms
Ganga Pharmaceuticals Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Ganga Pharmaceuticals's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ganga Pharmaceuticals Net Current Asset Value Chart
BOM:539680 vs ZTS: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ganga Pharmaceuticals's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ganga Pharmaceuticals Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ganga Pharmaceuticals's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Ganga Pharmaceuticals's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of ₹10.53 mean?
Ganga Pharmaceuticals (BOM:539680) has a Net Current Asset Value of ₹10.53 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Ganga Pharmaceuticals and its competitors. This is 542% above median its historical median of 1.64. Over the past decade, Ganga Pharmaceuticals' Net Current Asset Value has ranged from 0.98 to 2.84.
Is Ganga Pharmaceuticals' Net Current Asset Value too high?
Ganga Pharmaceuticals' current Net Current Asset Value of ₹10.53 is 542% above median its 10-year median of 1.64. Over the past 10 years, this metric has ranged from a low of 0.98 to a high of 2.84. Overall, Ganga Pharmaceuticals has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Ganga Pharmaceuticals' Net Current Asset Value compare to ZTS?
Ganga Pharmaceuticals' Net Current Asset Value of ₹10.53 can be compared against companies in the Drug Manufacturers industry. The industry median Net Current Asset Value is 5.70. Historically, Ganga Pharmaceuticals' own Net Current Asset Value has ranged from 0.98 to 2.84 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.70, based on 609 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Ganga Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ganga Pharmaceuticals's current Net Current Asset Value is ₹10.53, which is 542% above median its own 10-year median of 1.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ganga Pharmaceuticals stock overvalued right now?
Ganga Pharmaceuticals (BOM:539680) has a current Net Current Asset Value of ₹10.53. The stock's GF Value™ is ₹11.85, compared to a current price of ₹12.00 — trading 1.3% above its estimated fair value. The current Net Current Asset Value is ₹10.53, which is 542% above median its 10-year median of 1.64. Ganga Pharmaceuticals' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Ganga Pharmaceuticals (BOM:539680), the current Net Current Asset Value is ₹10.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ganga Pharmaceuticals (BOM:539680) Overvalued in 2026?
Based on GuruFocus' analysis, Ganga Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹12.00 is trading 1.3% above its estimated GF Value™ of ₹11.85.
Key valuation signals for BOM:539680:
Net Current Asset Value: ₹10.53 (542% above median its 10-year median of 1.64)
GF Value™: ₹11.85 vs. price of ₹12.00 (1.3% above fair value)
No single metric tells the full story. See the BOM:539680 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ganga Pharmaceuticals Ltd is an India based producer of ayurvedic medicines. It is engaged in the business of manufacturing and trading in ayurvedic pharmaceuticals and allied products. The company is also involved in the marketing and distribution of bulk ayurvedic medicines. The firm offers ayurvedic medicines for acidity, anti-dandruff, anti-oxidants, dental care, diarrhea, iron tonic, liver disorder, weight management, kidney stone, joint pains, liver disorder and others.
62GF Score
Get the complete analysis for BOM:539680
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539680 has been successfully added to your 
